JP2024537137A - Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 - Google Patents

Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 Download PDF

Info

Publication number
JP2024537137A
JP2024537137A JP2024520703A JP2024520703A JP2024537137A JP 2024537137 A JP2024537137 A JP 2024537137A JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024537137 A JP2024537137 A JP 2024537137A
Authority
JP
Japan
Prior art keywords
kras
irinotecan
inhibitor
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537137A5 (https=
Inventor
ハリン，ジル
クリステンセン，ジェームズ・ゲイル
ボウカット，ビッキー
オルソン，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2024537137A publication Critical patent/JP2024537137A/ja
Publication of JP2024537137A5 publication Critical patent/JP2024537137A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024520703A 2021-10-05 2022-10-04 Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 Pending JP2024537137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
US63/252,405 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024537137A true JP2024537137A (ja) 2024-10-10
JP2024537137A5 JP2024537137A5 (https=) 2025-09-30

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520703A Pending JP2024537137A (ja) 2021-10-05 2022-10-04 Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法

Country Status (10)

Country Link
US (1) US20250249003A1 (https=)
EP (1) EP4412720A4 (https=)
JP (1) JP2024537137A (https=)
KR (1) KR20240073115A (https=)
CN (1) CN118354794A (https=)
AU (1) AU2022361219A1 (https=)
CA (1) CA3233571A1 (https=)
IL (1) IL311863A (https=)
MX (1) MX2024004214A (https=)
WO (1) WO2023059600A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
IL311863A (en) 2024-06-01
KR20240073115A (ko) 2024-05-24
CA3233571A1 (en) 2023-04-13
EP4412720A1 (en) 2024-08-14
WO2023059600A1 (en) 2023-04-13
MX2024004214A (es) 2024-07-29
EP4412720A4 (en) 2025-08-13
CN118354794A (zh) 2024-07-16
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
JP2024537137A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法
JP7546549B2 (ja) 組み合わせ療法
JP2025000630A (ja) 組み合わせ療法
CN118382459A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
JP2025148403A (ja) 組み合わせ療法
JP2024537139A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法
KR20210113587A (ko) 병용 요법
JP2025000629A (ja) 組み合わせ療法
JP2024540839A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
JP2024521788A (ja) 併用療法
CN119031916A (zh) 包含sos1抑制剂和egfr抑制剂的组合疗法
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
HK40108579A (zh) Kras g12d抑制剂与伊立替康的组合及相关治疗方法
JP2025513802A (ja) Ｓｏｓ１阻害剤及びｍｅｋ阻害剤を含む併用療法
CN113840823B (zh) 显示癌细胞生长抑制效果的新型杂环取代的嘧啶衍生物，以及包含其的药物组合物
HK40108895A (zh) Kras g12d抑制剂与pi3ka抑制剂的组合及相关治疗方法
TW202428280A (zh) 組合療法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
TW201808300A (zh) σ受體配體在癌症中的用途
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
HK40101229A (zh) 组合疗法
HK40074319A (en) Combination therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919